Stock Alert: Sorrento Therapeutics Up 17%

(RTTNews) - Sorrento Therapeutics, Inc. (SRNE) shares are rising more than 17 percent on Monday morning trade as it got clearance from the FDA for the Phase 2 trial of Abivertinib in COVID-19 patients with severe pulmonary symptoms. Earlier on May 21, the company had acquired an exclusive license agreement for the novel molecule from ACEA Therapeutics. Abivertinib has been tried in over 600 patients worldwide in oncologic indications. The shares are currently at $8.17, up 17.22 percent from its previous close of $6.97.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


    Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

    Learn More